Localized Prostate Cancer COE

The Molecular Biology of Prostate Cancer - Christopher Barbieri

Details
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....

MRI and Active Surveillance for Prostate Cancer - Robert Reiter

Details
Rob Reiter and Alicia Morgans discuss the use of MRI and active surveillance in prostate cancer treatment. Dr. Reiter explains how MRI is used to improve proper patient selection for active surveillance. He also discusses how he was an early adopter of MRI and how he incorporates an MRI-guided biopsy program in his practice. In conclusion, Dr. Reiter and Dr. Morgans agree it’s important to note th...

The ENACT Trial: Ezalutamide Monotherapy plus Active Surveillance vs Active Surveillance Alone in Patients with Low-Risk or Intermediate-Risk Prostate Cancer - Neal Shore

Details
Neal Shore joins Alicia Morgans in a discussion on the ENACT Randomized Clinical Trial investigating the use of enzalutamide in prostate cancer patients who are starting on active surveillance (AS). They discuss the purpose of the study and Dr. Shore details the study design. There are few published studies prospectively assessing pharmacological interventions that may delay prostate cancer progre...

Who Needs Early Salvage Radiotherapy and Who Needs Adjuvant Radiotherapy in 2022? - Kosj Yamoah

Details
Kosj Yamoah joins Alicia Morgans in discussing a gray area in the management of biochemical recurrence. Kosj Yamoah presented on who needs early salvage radiotherapy and who needs adjuvant radiotherapy at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Meeting. The APCCC addresses key areas of prostate cancer management where there are uncertainties or areas where there is a lack of...

Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin

Details
Daniel Lin joins Alicia Morgans in highlighting a guideline-directed practical course on how to use genomics in clinical practice. Dr. Lin was part of the instructional course faculty at the AUA annual meeting. The learning objectives of this course include a discussion on the research studies that led to the approval of genomic testing for prostate cancer, ordering appropriate genomic testing bas...

Genomic Risk Classification in Localized Prostate Cancer - Matthew Cooperberg

Details
Matthew Cooperberg joins Alicia Morgans in a conversation on genomic risk classification in localized prostate cancer. They discuss the risk stratification of prostate cancer and where the use of this is most valuable. Dr. Cooperberg highlights this topic in terms of two basic categories of markers: the pre-diagnostic in terms of liquid tests and post-diagnostic settings. Biographies: Matthew Coop...

AUA Guidelines on Localized Prostate Cancer - Stephen Boorjian & James Eastham

Details
James Eastham and Stephen Boorjian join Alicia Morgans in a conversation on AUA Guidelines focused on localized prostate cancer. The guidelines provide a framework to have a conversation with a patient about their individual situation involving risk assessment, not only from the cancer standpoint but also from the treatment standpoint. These guidelines provide the framework of what physicians shou...

Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz

Details
Laurence Klotz joins Phillip Koo at the 13th International Uro-Oncology Congress in São Paulo, Brazil in a discussion on Active Surveillance (AS), High-intensity focused ultrasound (HIFU), and focal therapy in Latin America and developing countries. There are challenges with active surveillance in developing countries that might not have formal prostate cancer screening programs, a lack of resourc...

Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp

Details
The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...

Racial and Ethnic Disparity in the Use of Prostate MRI - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen review the publication titled "Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test." The study evaluated the association between race and ethnicity and the mean time between prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Among men with elevated PSA results...
email news signup